Abstract Learning Objectives After completing this course, the reader will be able to:
Consider tumor histology when making treatment decisions for patients with NSCLC. Identify …

Pemetrexed (Alimta; Eli Lilly), a next-in-class antifolate drug, was first approved by the US
Food and Drug Administration (FDA) in 2004 in combination with cisplatin for the treatment …

Objectives Retrospective subgroup analysis in JMDB study indicates that the between-arm
differences in overall survival (OS) in the East Asian subgroup were consistent with those …

Objectives The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was
efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung …

Purpose Cisplatin plus gemcitabine is a standard regimen for first-line treatment of
advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus …

Background Baseline patient and disease characteristics are investigated in non-small-cell
lung cancer (NSCLC) in an effort to predict response to treatment and optimize patients' …

Purpose This study evaluated the efficacy and safety of pemetrexed, carboplatin, and
bevacizumab followed by maintenance pemetrexed and bevacizumab in patients with …

PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of
advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus …

BACKGROUND: Although platinum-based doublet chemotherapy is considered as standard
of care for patients with advanced non-small cell lung cancer (NSCLC), most of them are …

Pemetrexed (Alimta®) is a multi-targeted antifolate cytotoxic agent available for use in the
treatment of adults with advanced non-squamous non-small cell lung cancer (NSCLC). It is …